Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Procter & Gamble Co (PG) vs Synopsys, Inc. (SNPS) Price & Performance

Procter & Gamble CoTrade
Synopsys, Inc.Trade

Price performance (Past 24H)

Key statistics

Procter & Gamble Co vs Synopsys, Inc. — how do they compare? Procter & Gamble Co trades at $143.48 (market cap $338.13B), while Synopsys, Inc. trades at $394 (market cap $75.13B). The key difference: Procter & Gamble Co is far larger — about 4.5× Synopsys, Inc.'s market cap, and Procter & Gamble Co pays a 2.99% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.

PGSNPS
Market Cap
$338.13B$75.13B
Volume
6,423,436
Sector
Consumer StaplesTechnology
52-Week High
$167.18$534.56
52-Week Low
$138.10$372.33
Enterprise Value
$363.97B$82.36B
Dividend Yield
2.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Procter & Gamble Co

Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including a net income margin of 18.44% and ROE of 30.13%, though valuation ratios like P/E of 21.99 and P/S of 4.05 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.

PG offers stability with consistent dividend growth and solid cash flows, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical weakness suggests potential consolidation. Key risks include economic sensitivity and competitive pressures, while institutional activity shows mixed positioning.

Synopsys, Inc.

Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.

The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Procter & Gamble Co

The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.

Read more on PG

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS